Bio-Path pre-clinical data shows BP1001-A restores insulin sensitivity, supporting obesity/T2D potential

BIO-PATH HOLDINGS, INC.

BP1001-A attenuated palmitic acid-induced insulin resistance in C2C12 myoblasts and myotubes.
Final pre-clinical mouse model study expected H1 2025; IND filing planned by year-end.
BP1001-A downregulates Grb2 expression to increase insulin sensitivity in muscle cells.
CEO cites need for alternative glucose-lowering treatments in obese T2D patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.